Three Consecutive Monthly Intravitreal Ranibizumab for Choroidal Neovascularization in Central Serous Choriorethinopathy: A Case Report


Purpose: The author report the result of three consecutive monthly intravitreal ranibizumab injection for choroidal neovascularization (CNV) after bevacizumab injection for chronic central serous rethinopathy (CSR). Methods: A 48 year old man with chronic CSR was treated with intravitreal single dose 2.5 mg bevacizumab. One year after CNV was occurred, and three consecutive monthly intravitreal ranibizumab injections were performed. Results: Four weeks later the first ranibizumab dose, best corrected visual acuity was improved 20/80 to 20/20 and remained stable within one year. Conclusion: Repeat intravitreal ranibizumab injection in CNV after bevacizumab injection for chronic CSR appeared to be an effective treatment option.

Share and Cite:

K. Erol, E. Sogutlu Sari, A. Koytak, A. Karaçor, D. T. Çoban and M. Bulut, "Three Consecutive Monthly Intravitreal Ranibizumab for Choroidal Neovascularization in Central Serous Choriorethinopathy: A Case Report," Open Journal of Ophthalmology, Vol. 2 No. 3, 2012, pp. 93-96. doi: 10.4236/ojoph.2012.23020.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] R. H. Loo, I. U. Scott, H. W. Flynn Jr., J. D. Gass, T. G. Murray, M. L. Lewis, P. J. Rosenfeld and W. E. Smiddy, “Factors Associated with Reduced Visual Acuity during Long-Term Follow-Up of Patients with ?diopathic Central Serous Chorioretinopathy,” Retina, Vol. 22, No. 1, 2002, pp. 19-24doi:10.1097/00006982-200202000-00004
[2] H. Matsunaga, K. Nangoh, M. Uyama, H. Nanbu, Y. Fujiseki and K. Takahashi, “Occurrence of Choroidal Neovascularization Following Photocoagulation Treatment for Central Serous Retinopathy,” Nihon Ganka Gakkai Zasshi, Vol. 99, 1995, pp. 460-468.
[3] W. M. Chan, T. Y. Lai, D. T. Liu and D. S. Lam, “Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy, Secondary to Punctate ?nner Choroidopathy, or of ?diopathic Origin,” American Journal of Ophthalmology, Vol. 143, No. 6, 2007, pp. 977-983. doi:10.1016/j.ajo.2007.02.039
[4] B. A. Cooper and M. A. Thomas, “Submacular Surgery to Remove Choroidal Neovascularization Associated with Central Serous Chorioretinopathy,” American Journal of Ophthalmology, Vol. 130, No. 2, 2000, pp. 187-191 doi:10.1016/S0002-9394(00)00395-0
[5] A. Koytak, K. Erol, E. Coskun, N. Asik, H. Oztürk, Y. Ozertürk, “Fluorescein Angiography-Guided Photodynamic Therapy with Half-Dose Verteporfin for Chronic Central Serous Chorioretinopathy,” Retina, Vol. 30, No. 10, 2010, pp. 1698-1703. doi:10.1097/IAE.0b013e3181da4354
[6] J. F. Arevalo, R. A. Garcia-Amaris, J. A. Roca, et al., “Primary Intravitreal Bevacizumab for the Management of Pseudophakic Cystoid Macular Edema Pilot Study of the Pan-American Colloborative Retina Study Group,” Journal of Cataract & Refractive Surgery, Vol. 33, No. 12, 2007, pp. 2098-2105. doi:10.1016/j.jcrs.2007.07.046
[7] D. Iturralde, R. F. Spaide, C. B. Meyerle, J. M. Klancnik, L. A. Yannuzzi, Y. L. Fisher, J. Sorenson, J. S. Slakter, K. B. Freund, M. Cooney and H. F. Fine, “Intravitreal Bevacizumab (Avastin) Treatment of Macular Edema in Central Retinal Vein Occlusion: A Short-Term Study,” Retina, Vol. 26, No. 3, 2006, pp. 279-284. doi:10.1097/00006982-200603000-00005
[8] D. Kook, A. Wolf, T. Kreutzer, A. Neubauer, R. Strauss, M. Ulbig, A. Kampik and C. Haritoglou, “Long-Term Effect of ?ntravitreal Bevacizumab (Avastin) in Patients with Chronic Diffuse Diabetic Macular Edema,” Retina, Vol. 28, No. 8, 2008, pp. 1053-1060. doi:10.1097/IAE.0b013e318176de48
[9] S. J. Lim, M. I. Roh and O. W. Kwon, “Intravitreal Bevacizumab ?njection for Central Serous Chorioretino- pathy,” Retina, Vol. 30, No. 1, 2010, pp. 100-106. doi:10.1097/IAE.0b013e3181bcf0b4
[10] J. Gaudreault, D. Fei, J. C. Beyer, A. Ryan, L. Rangell, V. Shiu, L. A. Damico, “Pharmacokinetics and Retinal Distribution of Ranibizumab, a Humanized Antibody Fragment Directed against VEGF-A, Following Intravitreal Administration in Rabbits,” Retina, Vol. 27, No. 9, 2007, pp. 1260-1266. doi:10.1097/IAE.0b013e318134eecd
[11] M. Wang, I. C. Munch, P. W. Hasler, C. Prünte and M. Larsen, “Central Serous Chorioretinopathy,” Acta Ophthalmologica, Vol. 86, No. 2, 2008, pp. 126-145. doi:10.1111/j.1600-0420.2007.00889.x
[12] K. B. Schaal, A. E. Hoeh, A. Scheuerle, F. Schuett and S. Dithmar, “Intravitreal Bevacizumab for Treatment of Chronic Central Serous Chorioretinopathy,” European Journal of Ophthalmology, Vol. 19, No. 4, 2009, pp. 613- 617.
[13] R. S, Kaiser, O. P. Gupta, C. D. Regillo, A. C. Ho, M. S. Fineman, J. F. Vander, J. A. McNamara and G. C. Brown, “Ranibizumab for Eyes Previously Treated with Pegap- tanib or Bevacizumab without Clinical Response,” Ophthalmic Surgery, Lasers and Imaging, Vol. 43, No. 1, 2012, pp. 13-19.
[14] P. J. Rosenfeld, J. S. Heier, G. Hantsbarger and N. Shams, “Tolerability and Efficacy of Multiple Escalating Doses of Ranibizumab (Lucentis) for Neovascular Age-Related Macular Degeneration,” Ophthalmology, Vol. 113, No. 4, 2006, pp. 623-632. doi:10.1016/j.ophtha.2006.01.027

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.